BRIEF-Sanofi: FDA Extends Target Action Date For Sarclisa Subcutaneous Review

April 22 (Reuters) - Sanofi SA SASY.PA:

  • PRESS RELEASE: SANOFI PROVIDES UPDATE ON THE REGULATORY SUBMISSION FOR SARCLISA SUBCUTANEOUS IN THE US

  • FDA EXTENDS TARGET ACTION DATE FOR SARCLISA SUBCUTANEOUS REVIEW BY UP TO THREE MONTHS

  • REVISED FDA TARGET ACTION DATE FOR SARCLISA SUBCUTANEOUS IS JULY 23, 2026

Source text: ID:nGNX8s1cbG

Further company coverage: SASY.PA


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.